Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatment with rio...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
格式: | Artigo |
语言: | 英语 |
出版: |
2018
|
在线阅读: | https://doi.org/10.1186/s12931-018-0957-y https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-018-0957-y |
标签: |
添加标签
没有标签, 成为第一个标记此记录!
|
成为第一个发表评论!